


Inflammatory markers as predictors of mortality in COVID-19 infection

**Authors:**

Awadia A. Ahmeidi¹ 
Ashraf Musa² 
Hend S. Ahmed³ 
Adel A. Elahmar⁴ 
Ryhana B. Goota⁵ 
Ibtihal A. Ahmed⁶ 
Abdelhakam H. Ali⁷ 
Mushal Allam⁸ 
Mozaan O. Hassan³ 

Affiliations:

¹Department Hematology, Faculty of Medical Laboratory Science, University of Science and Technology, Khartoum, Sudan

²Abeer Hospital, Muscat, Oman

³Department Hematology and Blood Transfusion, Faculty of Medical Laboratory Science, Omdurman Ahlia University, Khartoum, Sudan

⁴Communicable Disease Center, Harmad Medical Corporation, Doha, Qatar

⁵Ministry of Health, Khartoum, Sudan

⁶Faculty of Medical Laboratory Science, Ibn Sina University, Khartoum, Sudan

⁷Department Microbiology, Faculty of Medical Laboratory Science, University of Al Butana, Rufaa, Sudan

⁸National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa

Corresponding author:

Mozaan Hassan,
oh.mozan@gmail.com

Read online:

Scan this QR code with your smart phone or mobile device to read online.

Since the origination of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in China in December 2019 and its subsequent global spread, it became critical to understand the inflammatory process associated with this virus and the coronavirus disease 2019 (COVID-19) and to understand the changes associated with the different inflammatory parameters. The clinical presentation of COVID-19 cases varies greatly from mild symptoms among the majority of patients, to severe disease leading to death in some patients.

Many COVID-19 cases had increased levels of inflammatory cytokines and other infection-related biomarkers.¹ The inflammatory markers, including interleukin-6, D-dimer, neutrophil-to-lymphocyte ratio and high-sensitivity C-reactive protein (hs-CRP) levels, were found to be indicative of severe COVID-19 in reports that emerged from China.² However, their association with mortality among COVID-19 patients has not been reviewed. In this article, we identify inflammatory markers (interleukin-6, D-dimer, neutrophil-to-lymphocyte ratio and hs-CRP) as predictors of COVID-19 mortality. Laboratory tests for these markers are simple, cheap and available and can be performed in outbreak areas with limited resources.

According to Zhou et al., D-dimer levels exceeding 1.0 $\mu\text{g}/\text{mL}$ at hospital admission correlated significantly with death among hospitalised COVID-19 patients in China, with a *p*-value of less than 0.001.³ Another study in Wuhan, China, which included 343 in-patients with confirmed COVID-19, showed that elevated D-dimer levels over 2 $\mu\text{g}/\text{mL}$ at an early stage of hospitalisation correlated significantly with a high risk of death.⁴ Also, according to another study from China that included 1099 confirmed COVID-19 patients, results revealed that median D-dimer and C-reactive protein levels were higher among severe cases compared to non-severe cases, demonstrating that high D-dimer and C-reactive protein levels were significantly associated with COVID-19 severity.⁵ Additionally, in Wuhan Jinyintan Hospital, China, a study showed that high levels of interleukin-6 were significantly associated with a high mortality rate.⁶ This finding was corroborated by Silberstein in this study.⁷ Liu Y et al. in Zhongnan Hospital of Wuhan University identified an elevation in the neutrophil-to-lymphocyte ratio as an independent and significant predictor of mortality among 245 hospitalised COVID-19 patients, with an 8% increase in mortality with each unit increase in neutrophil-to-lymphocyte ratio.⁸

Many studies reported a correlation between high levels of hs-CRP and mortality rate in COVID-19 patients. A study done among 375 patients with confirmed SARS-CoV-2 infection revealed that elevated hs-CRP levels were significantly associated with a high mortality risk.⁹ In another study conducted to evaluate fatal outcomes among COVID-19 patients, 187 patients from China were included among whom 43 died, and results revealed that high levels of hs-CRP was significantly associated with mortality.¹⁰

We conclude that elevation in levels of these four inflammatory markers may be indicative of COVID-19 infection severity and mortality. We suggest that these parameters may be helpful predictors of COVID-19 severity and could be used as early predictors for case management before deterioration. On the other hand, these parameters cannot be used independently for initial diagnosis and physicians need to monitor the presence of other infections that may interfere with the elevation of these markers. Finally, we recommend that similar studies on inflammatory markers should be conducted in African populations to demonstrate the levels of these markers among African COVID-19 patients and their association with COVID-19 severity and mortality.

Dates: Received: 12 June 2020 | Accepted: 07 Oct. 2020 | Published: 21 Dec. 2020

How to cite this article: Ahmeidi A.A, Musa A, Ahmed H.S, et al. Inflammatory markers as predictors of mortality in COVID-19 infection. Afr J Lab Med. 2020;9(1), a1298. <https://doi.org/10.4102/ajlm.v9i1.1298>

Copyright: © 2020. The Authors. Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License.

Acknowledgements

Competing interests

The authors have declared that no competing interests exist.

Authors' contributions

A.A.A., A.M., A.A.E. and I.A.A. developed the concepts and performed the literature search. M.O.H. and M.A. helped to supervise the project. A.H.A and R.B.G. edited the manuscript. A.A.A., A.H.A. and A.A.E. prepared and reviewed the manuscript. H.S.A. helped in writing the literature review. M.A. and M.O.H. were responsible for final approval of the version to be published.

Ethical considerations

This article followed all ethical standards for research without direct contact with human or animal subjects.

Sources of support

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Data availability statement

Data sharing is not applicable to this article as no new data were created or analysed in this study.

Disclaimer

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any affiliated agency of the authors.

References

1. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clin Infect Dis*. 2020;71(15):762–768. <https://doi.org/10.1093/cid/ciaa248>
2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. *Lancet*. 2020 Feb 15;395(10223):507–513. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)
3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet*. 2020;395(10229):1054–1062. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
4. Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in hospital mortality in patients with Covid-19. *J Thromb Haemost*. 2020 Jun;18(6):1324–1329. <https://doi.org/10.1111/jth.14859>
5. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020 Apr 30;382(18):1708–1720.
6. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med*. 2020;180(7):934–943. <https://doi.org/10.1001/jamainternmed.2020.0994>
7. Silberstein M. Correlation between premorbid IL-6 levels and COVID-19 mortality: Potential role for Vitamin D. *Int Immunopharmacol*. 2020 Nov;88:106995. <https://doi.org/10.1016/j.intimp.2020.106995>
8. Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *J Infect*. 2020;81(1):e6–e12. <https://doi.org/10.1016/j.jinf.2020.04.002>
9. Yan L, Zhang HT, Goncalves J, et al. An interpretable mortality prediction model for COVID-19 patients. *Nat Mach Intell*. 2020;2(5):283–288. <https://doi.org/10.1038/s42256-020-0180-7>
10. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020;5(7):811–818. <https://doi.org/10.1001/jamacardio.2020.1017>